New York, USA – October 12, 2021 – Creative Biogene, the world’s leading biotechnology products, and services provider is committed to developing high-quality products and services, as well as proprietary technology to support the research in the field of basic life sciences research, biomedical development, industrial synthetic application, and preclinical drug discovery. With the support of an innovative portfolio of products and professional platforms, Creative Biogene announced the release of its virus-like particles to cover the full scope of biotechnology needs of early drug discovery and drug development.
Creative Biogene provides customized molecular biology reagents and professional technical services for customers in the field of life science research. The comprehensive product portfolio includes enzymes, PCR, vectors, transfection reagents, cDNA and shRNA, and technologies for transfecting stable cell lines.
A virus-like particle is an artificial protein structure whose overall structure is similar to its corresponding natural virus. They are similar to viruses that have self-assembly properties but lose their original infectivity due to genome modification. VLP is constructed symmetrically from hundreds of coat proteins, which can be genetically engineered to present a regularly arranged epitope chain at the desired position on the outer surface. Compared with monomeric or oligomeric protein carriers, VLP can not only provide a higher density of foreign protein per particle, but also support a unique three-dimensional conformation, which is particularly important for the presentation of conformational epitopes.
The Creative Biogene team has extensive experience in designing and developing VLP products, which can deliver integrated antigens through the arms of adaptive immunity. VLP-based vaccine formulations can significantly enhance antigen immunogenicity through the use of adjuvant aluminum salts. In addition, special methods will be used to reduce the accumulation of preservatives and VLP.
VLPs can be used as a perfect immunogen, which can trigger a highly effective immune response in the body. Creative Biogene has used the VLP immunization strategy to successfully cultivate many antibody binding agents, especially against viral antigens or membrane antigens. In addition, Creative Biogene can use VLP as a delivery system to deliver a variety of compounds, including DNA, siRNA, peptides, proteins and drugs.
With the high biocompatibility of VLPs, the team specializes in providing VLPs chemical modification services, such as probe coupling for in vivo and in vitro bioimaging applications. In addition, complex VLPs can be developed to achieve highly specific cell targeting. Alternative methods available include vitamins, peptides, nucleic acids and carbohydrate proteins.
“Creative Biogene has established an excellent platform for producing high-quality VLP. With the proprietary platform, we have produced a series of VLPs and are developing more.” said Marcia Brady, the marketing director of Creative Biogene, she also claimed, “Our experienced scientists assist to provide the best service and the most qualified products to meet every specific need of our customers all over the world.”
About Creative Biogene
Creative Biogene, as a top-of-its-kind company that holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.